News AstraZeneca PLC Nasdaq Stockholm

Equities

AZN

GB0009895292

Market Closed - Nasdaq Stockholm Other stock markets 11:29:51 2024-05-03 am EDT			5-day change	1st Jan Change
1,634 ^SEK	-1.21%		-0.73%	+20.72%

May. 03	Angle shares up on assay development deal with AstraZeneca	AN
May. 03	Angle shares up on assay development deal with AstraZenaca	AN

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Combination treatment could provide new standard-of-care for aggressive lymphoma	May. 03	AQ
AI Startup Fileread Names Former AstraZeneca Legal Leader as Chief Strategy Officer and General Counsel to Drive Product Development and Accelerate Growth	May. 03	AQ
Angle shares up on assay development deal with AstraZeneca	May. 03	AN
Astrazeneca - CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	May. 03	AQ
Angle shares up on assay development deal with AstraZenaca	May. 03	AN
Angle Plc to Supply Prostate Cancer Androgen Receptor Detection Assay to AstraZeneca	May. 03	MT
AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal	May. 03	AN
Confident start before US jobs data	May. 03	AN
InterContinental Hotels makes first-quarter progress	May. 03	AN
AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial	May. 02	MT
AstraZeneca: research into respiratory diseases	May. 02	CF
AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K	May. 02	PU
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	May. 02	BU
AstraZeneca Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	May. 02	CI
AstraZeneca PLC Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	May. 02	CI
AstraZeneca: encouraging results in lymphoma	May. 02	CF
AstraZeneca notes positive trial results for Calquence treatment	May. 02	AN
AstraZeneca's Blood Cancer Combo Extends Progression-free Survival in Late-stage Study	May. 02	MT
Ipsen: new President for North America	May. 02	CF
AstraZeneca PLC Announces Calquence combination improved PFS in 1L MCL	May. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT